Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Next Previous
X
Search
Trial Profile

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Propranolol (Primary)
  • Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 07 Jun 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2027.
    • 07 Jun 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2026.
    • 24 Jul 2023 Interventional Study Model changed to Parallel, Planned patient number hanged to 24, Avelumab and Nivolumab has been added in this study, hence number of treatment arms changed to 2, Primary endpoint has been amended and trial focus has been changed to Ar.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top